Public internet data has been largely exhausted for training AI models. The real competitive advantage and source for next-generation, specialized AI will be the vast, untapped reservoirs of proprietary data locked inside corporations, like R&D data from pharmaceutical or semiconductor companies.

The effectiveness of AI and machine learning models for predicting patient behavior hinges entirely on the quality of the underlying real-world data. Walgreens emphasizes its investment in data synthesis and validation as the non-negotiable prerequisite for generating actionable insights.

A key competitive advantage for AI companies lies in capturing proprietary outcomes data by owning a customer's end-to-end workflow. This data, such as which legal cases are won or lost, is not publicly available. It creates a powerful feedback loop where the AI gets smarter at predicting valuable outcomes, a moat that general models cannot replicate.

With powerful LLMs, reasoning, and inference becoming commoditized, the key differentiator for AI-powered products is no longer the model itself. The most critical factor for success is the quality of the underlying data. Unifying, protecting, and ensuring the accessibility of high-quality data is the primary challenge.

Since LLMs are commodities, sustainable competitive advantage in AI comes from leveraging proprietary data and unique business processes that competitors cannot replicate. Companies must focus on building AI that understands their specific "secret sauce."

The vague concept of a 'data network effect' is now a real defensibility strategy in AI. The key is having a *live*, constantly updating proprietary dataset (e.g., real-time health data). This allows a commodity model to deliver superior results compared to a state-of-the-art model without access to that live data.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.

The biggest obstacle to AI adoption is not the technology, but the state of a company's internal data. As Informatica's CMO says, "Everybody's ready for AI except for your data." The true value comes from AI sitting on top of a clean, governed, proprietary data foundation.